Forest also disputes Warner-Lambert's assertion that the Federal Trade Commission would not necessarily require a divestment in the event of a merger because of overlaps between Celexa and either AHP's Effexor or Pfizer's Zoloft. "We cannot comment on any action the FTC might take, but even to suggest that those three products are not directly competitive would certainly surprise the marketing department at Parke-Davis as well as the physicians they and we have both been calling on for more than a year," Solomon wrote
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth